Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RV591: Ad26.Mos4.HIV and CH505 TF chTrimer Vaccine Study
NCT06205056Phase 1Recruiting
- Sponsor
- U.S. Army Medical Research and Development Command
- Start
- Jan 2024
- Primary completion
- Dec 2025
- Modality
- Prophylactic Vaccines, Recombinant Proteins and Enzymes, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CH505 TF chTrimer + ALFQ and Ad26.Mos4.HIV in human immunodeficiency virus infection (HIV) (4 arms), sponsored by U.S. Army Medical Research and Development Command. Primary endpoints: Occurrence and severity of solicited local and systemic adverse events, Occurrence, severity, and relationship to vaccination of unsolicited adverse events and 2 more. Started Jan 2024; status: recruiting.
02
Drugs
CH505 TF chTrimer + ALFQAd26.Mos4.HIV
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT06205056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06205056.